lifestyle.celebhomes.net
Home
Sample Page
Author:
ADC Therapeutics SA
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
May 4, 2026
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
May 1, 2026
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
April 27, 2026
ADC Therapeutics Announces New Employee Inducement Grant
April 1, 2026
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
March 10, 2026
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
January 9, 2026
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
ADC Therapeutics Announces New Employee Inducement Grant
January 2, 2026
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
December 4, 2025
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
December 3, 2025
1
2
Next Page
→